{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02731",
      "entity_text" : "eculizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Both CH50 and circulating free eculizumab levels are the most promising markers of response in patients treated with eculizumab 22 and one group has suggested individualized dosing schedules based on eculizumab levels 24, but this strategy requires further validation.",
  "reading_complete" : "2020-08-03T15:27:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:26:37Z",
  "trigger" : "levels",
  "evidence" : [ "eculizumab levels" ],
  "pmc_id" : "4974426",
  "score" : 0
}